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Abstract. Renal cell carcinoma (RCC) is the most common
type of kidney cancer and recent developments in the molecular
biology of RCC have identified multiple pathways associated
with the development of this cancer. This study aimed at
analyzing the expression pattern of cytokeratin 18 (CK18) in
RCC patients and its prognostic relevance. We quantified
CK18 mRNA expression and protein using real-time reverse
transcription quantitative polymerase chain reaction (RT-
QPCR) and immunohistochemistry, respectively, in paired
tumor and non-tumor samples from 42 patients. Our data
indicate that CK18 mRNA and proteins levels increased with
advanced stage and grade of the disease. Using primary
(RCC5) and metastatic renal cell carcinoma (RCC5 met) cell
lines, we demonstrated that CK18 expression was 5-fold
higher in the metastatic as compared to the primary RCC cell
line and correlated with a migratory phenotype characterized
by a distinct elongated morphology as revealed by Phalloidin
staining. In addition, RCC5 met cells displayed an increased
capacity to attach to fibronectin and collagen which was lost
following CK18 knock-down. Our data also indicate that the
expression of CK18 was associated with increased Snail
expression which correlated positively with advanced disease
in RCC patients. The present findings suggest that CK18 may
play an important role in the progression of RCC and it may
be used as a new predictor for RCC.
Introduction
Renal cell carcinoma is the most common form of kidney
cancer arising from the renal tubule (1). It accounts for 3% of
all adult malignancies and is the most lethal of the common
urologic cancers (2). Approximately 20-30% of patients
present with metastatic disease, and 20-40% of patients
undergoing nephrectomy for clinically localized renal cell
carcinoma will develop metastases (3). Since renal-cell
carcinoma is highly resistant to chemotherapy, interleukin-2
or interferon-· are widely used as first-line treatment of
metastatic disease. Although tumor stabilization and regression
have been observed with immunotherapy, the clinical benefit
of this treatment is insufficient to halt the spread of disease.
Response rates with these cytokines are low and response
rates with metastatic renal cell carcinoma range from 15 to
30% (4). Recent advances in the understanding of the patho-
genesis, behavior, and molecular biology of metastatic renal
cell carcinoma (RCC) have paved the way for developments
that may enhance early diagnosis, improve prognostication,
and prolong survival (5,6).
In a variety of human malignancies, tumor progression
is associated with changes in intermediate filament (IF)
expression (7). IFs provide crucial structural support in higher
eukaryotic cells and accumulating evidence shows that IFs
also participate in various cellular activities including
stress responses, cell growth, cell death and cell migration.
In epithelial cells, the predominant IF proteins are the
keratins, a multigene family of proteins that are divided into
type I (K9-K20) and type II (K1-K8) subclasses. Members of
the two subclasses form non-covalent hetero-polymers in a
1:1 ratio, and are further assembled into keratin filaments. 
The expression of keratins is tissue specific, and is tightly
regulated during differentiation. Cytokeratin 8 (CK8) and
Cytokeratin 18 (CK18) are the major components of IFs in
simple-type epithelial cells, including those in the liver, lung,
kidney, pancreas, mammary gland and in tumors that arise
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from these organs. In this regard, CKs are particularly
useful tools for the surveillance of carcinomas. Besides their
cell structural support and their role in providing mechanical
stability to tissues, CKs are implicated in a range of patho-
logical phenotypes seen in patients bearing mutations in
epidermal keratins. In addition, evidence has shown that
CK18 filaments play an important role in modulating cellular
response (8,9). 
Snail is a zinc finger transcription factor that triggers the
epithelial-mesenchymal transition (EMT) by directly repressing
E-cadherin expression and has been implicated in tumor
progression (10,11). Recent data have provided evidence that
Snail expression is required for metastatic dissemination.
Currently, it seems that Snail may play a role in maintenance of
the invasive phenotype (12,13). While preliminary information
from expression microarray data sets from primary human
breast cancers suggests that high levels of Snail are correlated
with poor clinical outcome for women with early breast cancer
(14), the involvement of Snail in RCC progression and its
relationship with CK18 has not yet been established. Although
to date, a small number of possible marker genes are known
to predict RCC behavior more accurately, a reliable marker
for early diagnosis of RCC has not been reported (15). Since
RCC is believed to arise from proximal tubule epithelium
(16,17) and in order to identify new prognosis markers for
clear cell RCC, we have examined in the present study the
relationship between CK18 and Snail expression in RCC.
Our findings point to the existence of a relationship between
CK18 and RCC progression as well as a role for Snail during
this process.
Patients and methods
Patients. The immunohistochemistry study was based on
data obtained from the treatment of 40 clear cell carcinomas
surgically resected between 2004 and 2008 at the Division of
Urology, Charles Nicolle Hospital, Tunisia. Hematoxylin
and eosin (H&E) stained sections for all 40 specimens were
reviewed in a blind manner by one pathologist (Table I).
Samples for RT-QPCR were obtained from 42 patients with
histologically confirmed clear cell subtype RCC, who had
not received pre-operative therapy (Table II). Tumors were
resected between 2006 and 2009. The staging of tumors was
carried out according to the International Union against Cancer
(UICC) standards, based on routine imaging methods and
laboratory tests. Normal renal tissue (n=5) obtained from
kidneys removed because of benign diseases were used to
normalize real-time PCR experiments. Appropriate written
consent was obtained to use the material in our study.
Cell lines. Primary and metastatic renal cell carcinoma cell
lines RCC5 and RCC5 met respectively were obtained from the
same patients with conventional RCC as described previously
(18). Cells were cultured in DMEM/F12 1:1 medium con-
taining 10% heat inactivated FCS, 2 mM L-glutamine, 1 mM
sodium pyruvate and 1% Ultroser G (Gibco BRL, Life Techno-
logies, Cergy Pontoise, France) at 37˚C in a humidified
atmosphere containing 5% CO2. NK cells were negatively
selected from healthy donor peripheral blood mononuclear
cells with NK cell isolation kit II (Miltenyi Biotech).
Immunochemistry. Immunohistochemistry was performed on
formalin-fixed, paraffin wax embedded samples. Immuno-
staining was performed with the mouse anti-human CK18
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Table I. Summary of clinicopathological findings for RCC
patients (immunohistochemistry).
–––––––––––––––––––––––––––––––––––––––––––––––––
Characteristics No. of cases (n=42)
–––––––––––––––––––––––––––––––––––––––––––––––––
Sex
Male 23
Female 19
Metastasis at first diagnosis 3
or recurrent metastasis
Tumor stage
pT1 17
pT2 17
pT3 8
pT4 0
Tumor grade
I 7
II 13
III 22
IV 0
–––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Summary of clinicopathological findings for RCC
patients (real-time PCR).
–––––––––––––––––––––––––––––––––––––––––––––––––
Characteristics No. of cases (n=42)
–––––––––––––––––––––––––––––––––––––––––––––––––
Sex
Male 24
Female 16
Metastasis at first diagnosis 1
or recurrent metastasis
Tumor stage
pT1 21
pT2 15
pT3 4
pT4 0
Tumor grade
I 12
II 13
III 15
IV 0
–––––––––––––––––––––––––––––––––––––––––––––––––
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antibody (1:100, clone DC10, Dako) and the Dako ChemMate
Detection kit. Application of the primary antibody was
followed by incubation with biotinylated goat anti-mouse
immunoglobulin secondary reagent (1:100) for 35 min. After
rinsing in TBS, the slides were then incubated in Dako Duet
(K0492) streptavidin-biotin-horseradish peroxidase complex
for 35 min, rinsed in TBS and mounted. 
The number of CK18-positive cells by immunostaining in
each tumor sample was estimated by the same pathologist
in a consecutive analysis of all samples on 1 day to ensure
maximal internal consistency. The staining results were
grouped into normal CK18 expression (100% stained cells),
heterogeneous CK18 expression (>10% and <100% stained
cells), and complete loss of CK18 expression (<10% stained
cells).
Real-time reverse transcription quantitative polymerase chain
reaction (RT-QPCR). Total RNA extraction was performed
with TRIzol reagents. Tissue expression of CK18 and Snail
was analyzed using single-stranded cDNA synthesized from
1 μg of total RNA by SuperScript RTII (Life Technologies,
Inc.) and a random hexamer primer. Each gene was run in
duplicates (40 cycles at 95˚C for 15 sec and 60˚C for 1 min)
using SYBR Green chemistry on the ABI PRISM 7700
Sequence Detection System (Applied Biosystems, Weiterstadt,
Germany). Samples were independently analyzed 2-3 times.
Primer sequences (forward and reverse) were as follows:
CK18, 5'-GAGCCTGGAGACCGAGAAC-3' and 5'-TTG
CGAAGATCTGAGCCC-3'. Snail, 5'-GAGGCGGTGG
CAGACTAG-3' and 5'-GACACATCGGTCAGACCAG-3'.
Data analysis involved the ΔCT method for relative quanti-
fication.
Confocal microscopy. Tumor cells were grown on glass
coverslips, fixed with 3% formaldehyde/PBS for 10 min
and permeabilized with 0.1% Triton X-100/PBS for 5 min,
followed by blocking with 1% bovine serum albumin/PBS
for 20 min. The fixed cells were then stained with Alexa
Fluor 568-phalloidin (Molecular Probes) for actin staining
and with anti-CK18 antibody for CK18 staining followed
by Alexa-488 secondary antibody (Molecular Probes). Cover-
slips were mounted with Vectashield (Vector Laboratories,
Burlingame, CA) and analyzed by a Zeiss laser scanning
confocal microscope (LSM-510, Jena, Germany). Images were
later on analyzed by using LSM Image Examiner software
(Zeiss).
Western blot analysis. Western blotting was performed as
described earlier (19). Total cellular extracts were prepared by
lysing cells in ice-cold buffer containing 1% NP40, 1 mmol/l
phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and 10 μg/
ml leupeptin. Equivalent protein extracts (30-50 μg) were
denatured by boiling in SDS and ß-mercaptoethanol, separated
by SDS-PAGE, and transferred onto nitrocellulose membranes
(Pierce/Perbio). Blots were then blocked for 1 h with TBS
containing 5% non-fat dry milk and probed with appropriate
antibody for 3 h with either anti-CK18 (mouse mAb, Dako)
or anti-Snail (mouse mAb, Cell Signaling). After washing,
blots were incubated with appropriate horseradish peroxidase-
conjugated secondary antibody. The complexes were detected
using SuperSignal West Pico Chemiluminescent Substrate
(Pierce/Perbio).
RNA interference. Gene silencing of CK18 expression was
performed by using sequence-specific siRNA, purchased from
Qiagen. RNAi experiments were performed as previously
reported (19). Briefly, cells were transfected by electro-
poration with 200 pmol siRNA in a Gene Pulser Xcell
Electroporation System (Bio-Rad; 300 V, 500 μF) and then
allowed to grow for 72 h. Human siRNA target sequences
used for CK18 were 5'-GCCGGAUAGUGGAUGGCAA-3'
and 5'-GCAUCGUUCUGCAGAUUGA-3'. SiRNA targeting
Luciferase, purchased from Sigma-Proligo, was used as a
negative control.
Wound healing (migration) assay. RCC5 and RCC5 met were
seeded at 1x106 in 60-mm diameter culture dishes. Cells were
gently scraped with a plastic tip to make wounds. The
medium was removed, cells were washed twice with PBS,
and serum-free medium was added along with mitomycin-D.
The cells were allowed to migrate into the area of wounds for
24 and 48 h. Afterwards, cultures were fixed in 4% para-
formaldehyde and stained with 0.5% crystal violet. Migration
was assessed by taking pictures of three different regions of
each wound at 24 and 48 h. Results are representative of
three separate experiments.
Adhesion assay. Ninety-six-well plates were coated with
type-I collagen (3 μg/ml), type-IV collagen (3 μg/ml),
osteopontin (5 μg/ml), or fibronectin (5 μg/ml) overnight at
4˚C and washed with PBS as described earlier (20). Briefly,
cells were detached with PBS-EDTA and seeded in serum-
free medium at a concentration of 104 cells/well. After 1 h at
37˚C wells were gently washed with phosphate-buffered
saline, and attached cells were fixed in 4% paraformaldehyde
and stained with 0.5% crystal violet. Absorbance of each
well was read at 620 nm in a plate reader. Results are
expressed as mean value of triplicate determinations.
Cell death analysis. Cells were plated in a 6-well plate at a
density of 5x104 cells/well and grown overnight. The medium
was replaced with either fresh medium (control medium)
or with medium supplemented with various concentrations
of TRAIL. Early apoptosis was assessed by flow cytometry
using Dioc6 and propidium iodide staining analyzed on a
FACSCalibur flow cytometer. Data were processed using
CellQuest software (Becton-Dickinson) as previously reported
(21).
Cytotoxic activity assay. The cytotoxic activity of the NK cells
was measured by a conventional 4-h Cr51 release assay (22) by
using triplicate cultures in round-bottomed 96-well plates. After
4 h of co-culture supernatants were transferred to LumaPlate-
96-wells (Perkin-Elmer), dried down, and counted on a Packard
TopCount NXT. Percentage of specific cytotoxicity was
calculated conventionally.
Statistical analysis. RT-QPCR results are presented as means
± SD per group. ANOVA was used to compare groups,
followed by multiple comparisons using Bonferroni's post-
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1145-1154.qxd  17/3/2010  01:02 ÌÌ  ™ÂÏ›‰·1147
test and t-test. In all cases, differences were considered
significant at: *P<0.05; **P<0.01; ***P<0.001.
Results
The increased expression of CK18 and Snail in RCC patients is
associated with advanced tumor stages. CK18 expression
was analyzed in RCC tumors from 42 patients by immuno-
chemistry using anti-CK18 mAb on formalin fixed, paraffin
wax embedded samples. As shown in Fig. 1A, positive CK18
staining was found in the cell membrane and cytoplasm of all
normal tissues of proximal and distal tubules and collecting
ducts, while no or weak CK18 expression was observed in the
glomerular cells. For RCC patients, three groups were clearly
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Figure 1. Relationship between CK18, Snail levels and RCC progression. (A) Cytokeratin 18 (CK18) expression levels in renal cell carcinoma (RCC).
Immunohistochemical staining of normal kidney and RCC tumors with CK18 monoclonal antibody. Overview of 3 groups of patients according to CK18
expression rate (bar, 25 μm). a, Normal kidney. b, Patients with <10% stained tumor cells. c, Patients with 10 to100% (>10% and <100%) stained tumor cells.
d, Patients with 100% stained tumor cells. (B) Relationship between immunohistochemical CK18 expression and clinical features. a, Correlation between
CK18 expression and tumor stage: percentage of patients with 100% stained tumor cells. b, Correlation between CK18 expression and tumor grade:
percentage of patients with 100% stained tumor cells. (C) Relationship between CK18 mRNA expression levels in RCC patients and clinical features.
Expression analysis for CK18 was performed by real-time PCR and was normalized to normal renal tissue. a, Correlation between CK18 expression and
tumor stage. b, Correlation between CK18 expression and tumor grade. (D) Relationship between Snail expression in RCC patients and clinical features.
Expression analysis by RT-QPCR for Snail is relative to 18S rRNA and normalized to normal renal tissue. a, Correlation between Snail expression and tumor
stage. b, Correlation between Snail expression and tumor grade.
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distinguishable according to the rate of CK18 expression in
tumor cells: patients with <10% stained tumor cells (Fig. 1Ab),
patients with heterogeneous stained tumor cells (>10% and
<100%, Fig. 1Ac) and patients with 100% stained tumor cells
(Fig. 1Ad). Data depicted in Fig. 1B and C (RT-QPCR)
indicate that CK18 expression increases according to stage
and grade of RCC. We next explored possible correlations
between CK18 expression levels and various clinicopathologic
characteristics in RCC cases. We evaluated the expression
pattern of CK18 by immunohistochemical analysis. We
observed that CK18 mRNA levels in human RCC specimens
significantly correlate with tumor grade and stage. These
results suggest that the CK18 expression pattern could be
of predictive value as a marker of disease progression.
In order to evaluate the existence of a correlation between
Snail expression and RCC progression, RT-QPCR analysis
was performed on patient samples. Similar to what was seen
with CK18, we observed that relative Snail expression was
higher in RCC patients with either advanced disease stage T3
or advanced disease grade GIII (Fig. 1D). 
Differential expression of CK18 and Snail in primary and
metastatic RCC cell lines. We investigated CK18 and Snail
expression in primary (RCC5) and metastatic (RCC met)
RCC cell lines we had previously established from RCC patient
biopsies. Using RT-QPCR, data shown in Fig. 2A indicate
that the metastatic RCC cell line expressed ~5-fold higher
levels of CK18 mRNA than the primary cells. Similarly the
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Figure 2. CK18 and Snail levels in primary (RCC5) and metastatic (RCC5 met) cell lines. (A) The expression of CK18 and Snail genes in primary RCC5 and
metastatic RCC5 met cell lines was assessed by quantitative RT-PCR. Columns represent mean of three independent experiments; bars, ±S.D. **P≤0.01.
Experimental values were normalized to those for the 18S gene. (B) CK18 and Snail expression in RCC5 and RCC5 met cells was determined by Western blot
analysis. Actin was used as a loading control. (C) Confocal microscopy analysis of CK18 and Snail protein levels in RCC5 and RCC5 met. Cells were grown on
glass coverslips, stained with the appropriate antibody and followed by staining with Alexa-488 secondary antibody. Zeiss Axiovert 200 inverted fluorescence
microscope was used for analysis. Data are from one representative experiment of at least three.
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expression of Snail was higher in RCC5 met as compared
to RCC5. Fig. 2B shows the results of Western blot analysis
confirming the increased expression of CK18 and Snail
proteins in the metastatic RCC cell line. These observations
were further confirmed by confocal microscopy analysis
(Fig. 2C) showing an over-expression of CK18 and Snail
in the metastatic RCC5 cell line. 
The increased expression of CK18 does not interfere with RCC
cell response to NK-mediated cytotoxicity and TRAIL-induced
apoptosis. We asked whether the differential expression of
CK18 by RCC5 and RCC5 met cell lines correlates with their
susceptibility to NK cell- and TRAIL-induced cell death by
investigating their cytotoxic response to human NK cells
and to TRAIL. Data shown in Fig. 3A clearly indicate that
the killing response by cytotoxic effectors (NKL, TALL
and peripheral NK) was not affected by the level of CK18
expressed in primary and metastatic targets. In addition, the
data depicted in Fig. 3B indicate that RCC5 and RCC5 met
display a similar cytotoxic response following treatment
with TRAIL suggesting that CK18 does not interfere with the
apoptotic machinery in these cells.
Differential adhesive and migratory potential of RCC5 and
RCC5 met. Phalloidin staining revealed morphological changes
observed in metastatic cells as compared to the primary
cell line. In fact, RCC5 met display a migratory phenotype
characterized by an elongated morphology, disorganized actin
cytoskeleton and the presence of cell extensions associated
with a marked increase in filamentous actin cellular content
(Fig. 4A). We compared also the adhesive properties of the
two RCC cell lines to defined components of the extracellular
matrix. We found that metastatic cells RCC5 met attach better
to different cell matrices especially fibronectin and collagen I
in comparison to the primary cells RCC5 (Fig. 4B).
We next examined the cell motility of RCC5 and RCC5 met
on plastic substrate by determining the rate of wound closure
after scraping cells from an area of monolayer cultures.
Confluent monolayer cells were scraped, and cells were
allowed to migrate for 24 and 48 h in serum deprived medium
added with mitomycin-C to inhibit cell proliferation. Primary
cell line RCC5 showed an obviously slower closure rate at both
24 and 48 h when compared with metastatic cells RCC5 met
(Fig. 4C).
Silencing of CK18 in RCC5 met resulted in the loss of the
migratory phenotype. To further assess the putative role of
CK18 in migration and adhesion of metastatic cells, trans-
fection of RCC5 met cell line with small interfering RNA
(siRNA) targeting CK18 was performed. A specific and
efficient reduction of the level of CK18 protein as compared to
control siRNA was observed 72 h after transfection (Fig. 5A).
Knockdown of CK18 was accompanied by a decrease in
adhesion of metastatic cells to fibronectin and collagen I
(Fig. 5B). In addition, as depicted in Fig. 5C, CK18 silencing in
RCC5 met resulted in morphological changes showing that
RCC5 met acquired shape and monolayer organization similar
to that exhibited by RCC5 cells. We further demonstrated
that the loss of CK18 in the RCC5 met resulted in the loss of
elongated cells (Fig. 5C). All these changes may reflect an
attenuation of cell migratory properties.
Discussion
Renal cell carcinoma (RCC) represents five percent of adult
epithelial cancers and clear cell RCC is the most frequent
histological subtype. Improved understanding of the molecular
pathways implicated in the pathogenesis of RCC has led to
the development of specific targeted therapies to treat the
disease. In particular, CK18 is attracting considerable interest
as a response biomarker during clinical trials of anticancer
drugs. Given the important role of CK18 in cell adhesion,
cell migration, and signal transduction, which are of major
importance in tumor invasion and metastasis, it seemed
reasonable to investigate the effect of CK18 expression on
patient outcome in renal cell carcinoma. Here we evaluated
the expression pattern of CK18 in renal cell carcinoma by
immunohistochemical analysis of RCC tumors and studied the
correlation between CK18 expression and tumor stage and
grade. The comparison of the CK18 expression pattern with
different clinicopathological risk factors revealed a highly
significant correlation to the size and differentiation grade
of the tumor. These parameters are, among other factors, a
MESSAI et al:  CK18 EXPRESSION IN RCC PROGRESSION1150
Figure 3. Sensitivity of RCC5 and RCC5 met to NK, TALL and TRAIL
mediated lysis. (A) RCC5 and RCC5 met were co-cultured with NK cell
line, NK isolated from healthy donors and TALL-104 (ATCC CRL-11386).
Cytotoxicity was determined by a conventional 4-h Cr51-release assay with
different effectors at different ratios. Bars, ±SD. (B) RCC5 and RCC5 met
tumor cells were incubated with recombinant Trail (150, 300 and 600 μg/ml)
for the indicated times, and cell death was measured by DIOC6 and PI
staining.
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function of the proliferative rate of the primary tumor,
suggesting a possible relationship between higher CK18
expression and increased proliferative activity and survival.
Moreover, we observed in some early stages and low grade
tumors the loss of expression of CK18 as compared with
normal renal cells. According to these observations, three
hypotheses could be advanced to explain the variation level
of CK18 expression in RCC following tumor grades and stages:
i) decreased CK18 expression is only needed in low tumor
grades and stages to have tumor progression; this expression
may be restored in high tumor grade; ii) combination of
mutations in different genes may be associated with the weak
CK18 expression in low grade phenotype; or iii) the immune
system may be effective at low grades of RCC in eliminating
CK18 expressing tumor cells but ineffective at high grades.
Recently, Walter et al reported a high frequency of CK18
specific CD8 T cells in healthy donors using an HLA-A2
tetramer refolded with a nonameric peptide isolated from
RCC primary tumor (23,24). These potentially autoreactive
T cells may play an essential role in controlling tumor growth. 
This suggests an important functional role of this protein
in the development or progression of the disease. The variation
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Figure 4. Differential adhesive and migration properties of RCC5 and RCC5 met. (A) RCC5 and RCC5 met were grown on glass coverslips and stained with
Rhodamine-phalloidin before analyzing with a Zeiss Axiovert 200 inverted fluorescence microscope. (B) Renal carcinoma cell line adhesion. RCC5 and
RCC5 met were tested for their ability to adhere to osteopontin, collagen I, collagen IV and fibronectin. Results are expressed in optical density units (OD)
units as a mean of triplicate values ± SD. (C) Renal carcinoma cell line migration assay. RCC5 and RCC5 met were permitted to migrate into the wound area
of monolayer cultures and photomicrographs were taken at 24 h. Results are representative of three separate experiments.
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of CK18 at protein levels seems to be correlated with mRNA
level. The results presented here show that advanced tumor
grade and stage of RCC are associated with CK18 mRNA
expression. It should be noted that several correlative studies
between CK18 expression and prognostic value were pre-
viously established with discrepant results depending on the
primary tumoral site. In this respect, an association between
the induction of CK18 and a poor prognostic outcome has
been established in carcinoma of the oral cavity (25) and in
non-small cell lung cancer (26). Cintorino et al suggested that
CK8, CK18 and CK19 expression and distribution patterns
could be of predictive value as markers of disease progression
as defined by the appearance of lymph node metastases in
oesophageal squamous cell cancer (27). 
In this context, one issue was to identify the functional
consequences of such expression on tumor behaviour. For
this purpose, we used a primary RCC cell line and its metastatic
derivative which we have previously established (18). We
assessed first using different methods the differential behaviour
of the primary and metastatic cell lines including their
susceptibility to NK- and Trail-induced cell death and of their
adhesion and migration capability. We found that the two cell
MESSAI et al:  CK18 EXPRESSION IN RCC PROGRESSION1152
Figure 5. Cytokeratin 18 knock-down resulted in the modulation of RCC5 met tumor cell morphology and its adhesive and migratory properties. (A) Knock-
down of CK18 down-regulates the protein expression. RCC5 met cells were transfected with either 2 different sequences of CK18 siRNA, or scramble control
siRNA (control). Whole-cell lysates were subjected to SDS-PAGE, blotted, and probed with a specific antibody, as indicated. Actin was used as a loading control.
(B) RCC5 met transfected with control siRNA (CT) or CK18 siRNA were tested for their ability to adhere to collagen I and fibronectin. Results are expressed
in optical density units (OD) units as a mean of triplicate values ± SD. (C) RCC5 met transfected with control siRNA (CT) or CK18 siRNA were tested for
their ability to migrate in a wound healing assay. (D) RNA interference-mediated silencing of CK18 in RCC5 met was accompanied by a change in tumor cell
morphology.
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lines have the same response to NK cytotoxicity and Trail
induced apoptosis. However, RCC5 met cell line displays
morphological changes characteristic of migration phenotype
associated with higher adhesion and migration capability as
compared to RCC5 primary cell line. This would indicate
that, in this case, contrary to immune escape mechanisms, the
acquisition of a migratory phenotype is an important feature
for tumor progression. It is well established that epithelial
cell and tissue architecture is largely determined by cytoskeletal
filaments, which are part of an intracellular protein network
comprising the cytoskeleton itself, junctional complexes at
the cell border, and numerous associated proteins. Previous
studies showed that changes in the composition of the cyto-
skeleton expression result in an increased plasticity, which is
required for epithelial tumor cells to become mobile and
invasive. Indeed, most cancer cells do not have the physical
properties of leukocytes to invade tissues, circulate in the
blood, and re-enter new organs. Therefore, epithelial tumor
cells need to undergo a fundamental phenotypical change
called epithelial-to-mesenchymal transition (EMT) toward
more dedifferentiated and malignant states. To investigate
the functional consequences of CK18 overexpression and to
assess whether its expression patterns could represent putative
markers of tumor progression, we analysed CK18 mRNA
in both cell lines and found that CK18 was significantly
increased in metastatic RCC cell line. Moreover, siRNA
targeting CK18 in RCC5 met line resulted in attenuation of
cell migratory and adhesive properties. In the present study
we clearly indicate that over expression of CK18 correlated
with migratory phenotype characterized by a distinct elongated
morphology. Cytokeratin 18 appears to interfere with tumor
progression without attenuating tumor cell susceptibility to
cell or ligand mediated cytotoxicity despite a change in cell
morphology. Our findings fit with recent reports indicating
that elevated CK expression is associated with invasion
and metastasis and points to its involvement in dynamic cell
remodelling during cancer progression (26,28,29). They also
show that metastatic renal cells display increased cellular
motility, which might indicate increased tumor aggressiveness
and poor patient prognosis. However, findings from other
groups have challenged the value of CK18 as a putative
suppressor of tumor progression in breast cancer (30).
Several studies have associated changes in CK expression
with an altered cellular behaviour (31,32). In this respect, it
has been reported that the overexpression of the CK18 gene in
tumorigenic cells could result from a high level of acetylation
of histones and/or of factors controlling the activity of the
transcription complex (33).
In the course of these studies, we also showed that the
expression of the transcription factor Snail was positively
correlated with advanced disease in RCC patients. This fits
with its increased expression in RCC5 met as compared to
primary RCC line. This expression pattern of Snail in patients
and cell lines correlate with that of CK18. Taking into account,
this observation as well as Snail function and its role as
mediator of cell survival, we suggest that Snail could play a
role in the regulation of CK18 expression. Preliminary results
using siRNA targeting Snail in RCC5 met led to CK18
overexpression (data not shown) in spite of concomitant
increase of CK18 and Snail in high grades and stages. A
better understanding of the mechanisms associated with CK18
transcription and its involvement in the control of tumor
behaviour may therefore allow for the design of improved
therapeutic strategies in RCC. 
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